tiprankstipranks
Company Announcements

Chimeric Therapeutics Reports Increased Losses Amidst Asset Stabilization

Story Highlights
Chimeric Therapeutics Reports Increased Losses Amidst Asset Stabilization

The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).

Chimeric Therapeutics Limited reported a significant increase in losses for the half-year ended December 31, 2024, with a 216.9% rise in losses attributable to owners, totaling $2,857,887. Despite the financial setback, the company’s net tangible assets per ordinary security improved from (1.09) cents to (0.35) cents, indicating a potential stabilization in asset valuation. No dividends were declared for the current or previous financial periods, and the company’s financial statements were reviewed with a material uncertainty regarding its going concern status.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its proprietary CAR T cell therapy platform to address unmet medical needs in oncology.

Average Trading Volume: 4,603,630

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$10.37M

Learn more about CHM stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App